Patents by Inventor Gregg Timony

Gregg Timony has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS OF TREATMENT OF DISEASES IN WHICH IL-13 ACTIVITY IS DETRIMENTAL USING ANTI-IL-13 ANTIBODIES
    Publication number: 20230220061
    Abstract: The present invention is directed to methods for treating diseases in which IL-13 activity is detrimental, including eosinophilic esophagitis (EoE) and asthma, by administering to a subject in need of such treatment, a composition containing an interleukin-13 (IL-13) antibody, or an antigen binding fragment, thereof.
    Type: Application
    Filed: February 3, 2023
    Publication date: July 13, 2023
    Applicant: AbbVie Inc.
    Inventors: Gregg Timony, Sheila Gujrathi, Robert Peach, Allan Olson
  • METHODS OF TREATMENT OF DISEASES IN WHICH IL-13 ACTIVITY IS DETRIMENTAL USING ANTI-IL-13 ANTIBODIES
    Publication number: 20220281968
    Abstract: The present invention is directed to methods for treating diseases in which IL-13 activity is detrimental, including eosinophilic esophagitis (EoE) and asthma, by administering to a subject in need of such treatment, a composition containing an interleukin-13 (IL-13) antibody, or an antigen binding fragment, thereof.
    Type: Application
    Filed: May 10, 2022
    Publication date: September 8, 2022
    Applicant: AbbVie Inc.
    Inventors: Gregg Timony, Sheila Gujrathi, Robert Peach, Allan Olson
  • Methods of treatment of diseases in which IL-13 activity is detrimental using anti-IL-13 antibodies
    Patent number: 11390669
    Abstract: The present invention is directed to methods for treating diseases in which IL-13 activity is detrimental, including eosinophilic esophagitis (EoE) and asthma, by administering to a subject in need of such treatment, a composition containing an inter leukin-13 (IL-13) antibody, or an antigen binding fragment, thereof.
    Type: Grant
    Filed: April 27, 2017
    Date of Patent: July 19, 2022
    Assignee: Abbvie, Inc.
    Inventors: Gregg Timony, Sheila Gujrathi, Robert Peach, Allan Olson
  • METHODS OF TREATMENT OF DISEASES IN WHICH IL-13 ACTIVITY IS DETRIMENTAL USING ANTI-IL-13 ANTIBODIES
    Publication number: 20210380674
    Abstract: The present invention is directed to methods for treating diseases in which IL-13 activity is detrimental, including eosinophilic esophagitis (EoE) and asthma, by administering to a subject in need of such treatment, a composition containing an inter leukin-13 (IL-13) antibody, or an antigen binding fragment, thereof.
    Type: Application
    Filed: April 27, 2017
    Publication date: December 9, 2021
    Applicant: AbbVie Inc.
    Inventors: Gregg TIMONY, Sheila GUJRATHI, Robert PEACH, Allan OLSON
  • ORAL PHARMACEUTICAL FORMULATIONS AND METHODS FOR PRODUCING AND USING SAME
    Publication number: 20100063020
    Abstract: Oral pharmaceutical formulations and methods of producing and using the same are described and claimed. The formulations are dispersions of phospholipids and one or more pharmacologically active compounds, In preferred embodiments, the pharmaceutically active compounds are ansamycins, pharmaceutically acceptable salts, or prodrugs thereof.
    Type: Application
    Filed: September 4, 2009
    Publication date: March 11, 2010
    Inventors: Robert K. Mansfield, Edgar H. Ulm, Gregg A. Timony
  • PHOSPHOLIPID-BASED PHARMACEUTICAL FORMULATIONS AND METHODS FOR PRODUCING AND USING SAME
    Publication number: 20090238880
    Abstract: Pharmaceutical formulations and methods of producing and using the same are described and claimed. The formulations are dispersions of phospholipids and one or more pharmacologically active compounds, pharmaceutically acceptable salts thereof, or prodrugs thereof. In specific embodiments, the pharmaceutically active compounds are ansamycins and the overall formulation is substantially devoid of medium and long chain triglycerides.
    Type: Application
    Filed: February 12, 2009
    Publication date: September 24, 2009
    Inventors: Edgar H. Ulm, Robert K. Mansfield, Gregg A. Timony, Marcus F. Boehm
  • Phospholipid-based pharmaceutical formulations and methods for producing and using same
    Publication number: 20060228405
    Abstract: Pharmaceutical formulations and methods of producing and using the same are described and claimed. The formulations are dispersions of phospholipids and one or more pharmacologically active compounds, pharmaceutically acceptable salts thereof, or prodrugs thereof. In specific embodiments, the pharmaceutically active compounds are ansamycins and the overall formulation is substantially devoid of medium and long chain triglycerides.
    Type: Application
    Filed: April 7, 2006
    Publication date: October 12, 2006
    Inventors: Edgar Ulm, Robert Mansfield, Gregg Timony, Marcus Boehm
  • Oral pharmaceutical formulations and methods for producing and using same
    Publication number: 20060067953
    Abstract: Oral pharmaceutical formulations and methods of producing and using the same are described and claimed. The formulations are dispersions of phospholipids and one or more pharmacologically active compounds, In preferred embodiments, the pharmaceutically active compounds are ansamycins, pharmaceutically acceptable salts, or prodrugs thereof.
    Type: Application
    Filed: September 29, 2004
    Publication date: March 30, 2006
    Inventors: Robert Mansfield, Edgar Ulm, Gregg Timony